DEALS

Zhong Lun Advised on Anpac’s IPO on NASDAQ

Release time：2020-02-01 Voice Announcements

On January 31, 2020, Anpac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) completed its initial public offering of depositary shares, which have been listed on the Nasdaq Global Market.

Zhonglun Law Firm acted as Anpac’s PRC legal counsel in the offering. The legal team from Zhonglun was led by partners Anthony Zhao, William Jia, Xiong Chuan. Other project team members include lawyers Roy Zheng, Ye Yunting, etc. Xiao Ling, partner of Zhonglun's New York Office, provided strong support.

Anpac is a biotechnology company dedicated to early cancer screening. Anpac has certified clinical laboratories in China and the United States that perform a range of cancer screenings and tests, including CDA, biochemical tests, immunological and genetic tests.

Previous：Zhong Lun Advised on HUIZE’s IPO on NASDAQ Next：Zhong Lun Advises on JD’s US$1.0 billion Notes Offering

Print articles from Zhong Lun

Insights >

Publiciations >

Monthly Highlights >

Articles

Deals

Zhong Lun Assists Multiple Humanoid Robot and Intelligent Equipment Science and Technology Companies and Investors in Completing Tens of Millions Yuan Financing and Investment

Zhong Lun Advises on CR Beverage’s IPO in Hong Kong

Events

Awards

Zhong Lun Advised on Anpac’s IPO on NASDAQ